ClinicalTrials.gg
CompletedNCT03280745HERACLESUpdated Mar 24, 2020

Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery

A Phase 4 interventional study of Hypertonic saline and 0.9% saline in Cardiovascular Diseases and Valvular Heart Disease, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-24.

Primary conditionHeart Valve DiseasesRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Valve Diseases
Why
  1. The study's listed conditions name Heart Valve Diseases, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Heart Valve Diseases with a site in Switzerland — 8 open to participants now, 12 under way, none of them phase 3. Heart Valve Diseases · Switzerland.

Enrollment
11th of 19
165 · median 173
Started
2018
with 2 others
Phase 4
2 of 31
1 open now
Registered
14th of 31
by date
Lead sponsor
2 of 31
Insel Gruppe AG, University Hospital Bern

Among the 31 studies in Heart Valve Diseases with a site in Switzerland, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 4, and was the 14th registered.

Heart Valve Diseases

556 studies on the registry are indexed under Heart Valve Diseases; 166 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

8 of the 31 studies in Heart Valve Diseases with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Heart Valve Diseases with a site in Switzerland, or all of them as a file.
02

Study summary

Background: Volume replacement strategies and type of fluid used in patients undergoing cardiac surgery have changed during the last years. Currently used crystalloid solutes have a variable composition and a major impact on organ function and outcome. Additionally critically ill patients are prone to fluid overload, which is despite common perception, not a benign occurrence as it is associated with prolonged ICU- and hospital length of stay and increased mortality rates. Fluid resuscitation using bolus or continuous infusion of hypertonic saline was used for more than thirty years. Only a few studies have been conducted so far, but they showed that infusion of hypertonic saline results in less volume administered, increased renal function less weight gain in critically ill patients when compared to other crystalloids.

Aim: This preliminary randomized controlled double-blind study aims to identify whether fluid resuscitation using hypertonic saline (HS) when used in addition to lactated Ringers solution results in less total fluid amount administered in patients following cardiac surgery. Additionally we want to evaluate whether the use of hypertonic saline results less need for pharmacological cardiocirculatory support, increased renal function, less postoperative volume overload shortened post-cardiac bypass immune suppression and increased postoperative outcomes.

Study intervention: At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl or 0.9% NaCl by infusion pump over 60 minutes. If necessary, fluid resuscitation will thereafter be performed with Ringer's lactate to normalize peripheral perfusion and to allow weaning of vasopressors.

03

Conditions studied

  • Cardiovascular Diseases
  • Valvular Heart Disease

Browse trials for

04

In context

Heart Valve Diseases Reclassified

556 studies on the registry are indexed under Heart Valve Diseases; 166 are open to participants now.

This study's enrollment of 165 is above the median of 100 across 314 interventional studies indexed under Heart Valve Diseases.

Browse Heart Valve Diseases studies →

Lead sponsor

Insel Gruppe AG, University Hospital Bern is the lead sponsor of 742 studies on the registry; 180 are open to participants now.

Compared within Heart Valve Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients undergoing cardiac surgery for ischemic or valvular heart disease

Exclusion criteria

Exclusion Criteria:

  • Patients unable to give
  • Patients with age \<18 years
  • Pregnancy or breastfeeding
  • Left-ventricular (LVEF) \< 30% preoperatively
  • Preexisting renal insufficiency with an \<30 ml/min/1.73m2
  • Patients with postoperative circulatory support devices such as LVAD, IABP, Impella, ECMO
  • Preexisting serum sodium of >145mmol/l or \<135 mmol/L
  • Preexisting serum chloremia >107mmol/l or \< 98 mmol/L
  • Systemic therapy (at any dose at time of inclusion)
  • Chronic liver disease ( >3 mg.dl)
  • Any signs of infection or sepsis defined as clear clinical evidence for active infection or current antibiotic therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Active comparator
    7.3% NaCl (intervention)

    At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.

    Drug: Hypertonic saline

  • Active comparator
    0.9% NaCl (comparator)

    At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.

    Drug: 0.9% saline

Interventions

  • DrugHypertonic saline

    At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.

    Also known as: 7.9% NaCl

  • At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.

    Also known as: normal saline

07

What researchers measure

Primary outcomes

  1. total cumulative amount of fluids infused

    Time frame: daily until ICU discharge, max until postoperative day 90

Secondary outcomes

  1. postoperative weight gain

    Time frame: until postoperative day 6

  2. total postoperative cumulative urinary output

    Time frame: daily until ICU discharge, max until postoperative day 90

  3. total cumulative dose of inopressors per kg bodyweight /hour

    cumulation of norepinephrine and epinephrine

    Time frame: until ICU discharge, max until postoperative day 90

  4. time on inopressors

    norepinephrine and/or epinephrine

    Time frame: from ICU admission until stop of inopressors, max until postoperative day 90

  5. variation in renal function markers

    renal damage maker (TIMP2-IGFB, creatinine)

    Time frame: until postoperative day 6

  6. variation in acid-base homeostasis

    pH, base excess, lactate, bicarbonate, electrolytes

    Time frame: until postoperative day 6

  7. variation in immune function

    mHLA-DR

    Time frame: until postoperative day 6

  8. time on the ventilator

    Time frame: from ICU admission until time of extubation, maximum 90 days

  9. occurence of infection

    Time frame: occurence of infection during the index hospitalisation or subsequent admissions due to infection upto 90 postoperative days

  10. length of stay

    time to ICU/hospital-discharge

    Time frame: time to ICU/hospital-discharge however long this may take, maximum 90 days

  11. readmissions to the ICU

    Time frame: readmissions to the ICU within postoperative 90 days

  12. mortality

    Time frame: until postoperative day 90

08

Study locations

1 site
  • Department of Intensive Care, Bern University Hospital and University of Bern, Bern, Switzerland
    Bern, 3010, Switzerland
09

References and documents

Publications

  • Pfortmueller CA, Messmer AS, Hess B, Reineke D, Jakob L, Wenger S, Waskowski J, Zuercher P, Stoehr F, Erdoes G, Luedi MM, Jakob SM, Englberger L, Schefold JC. Hypertonic saline for fluid resuscitation after cardiac surgery (HERACLES): study protocol for a preliminary randomised controlled clinical trial. Trials. 2019 Jun 14;20(1):357. doi: 10.1186/s13063-019-3420-6. PubMed 31200756 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in May 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Sep 12, 2017
StartActual
Feb 27, 2018
Primary completionActual
May 27, 2019
CompletionActual
Sep 30, 2019
Last update
Mar 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03280745
Responsible party
Sponsor
First posted
Sep 12, 2017
Start date
Feb 27, 2018
Primary completion
May 27, 2019
Completion
Sep 30, 2019
Last update
Mar 24, 2020

Study contacts

Joerg C Schefold, MD
study director · Department of Intensive Care, Inselspital, Bern University Hospital, Bern, Switzerland

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion